Assessments of CYP-inhibition-based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo

• Published in: Pharmaceutical Biology Vol. 61; no. 1; pp. 356 - 361
• Main Authors: Zhou, Shan, Zhao, Fang-Ling, Wang, Shuang-Hu, Wang, Yi-Ran, Hong, Yun, Zhou, Quan, Geng, Pei-Wu, Luo, Qing-Feng, Cai, Jian-Ping, Dai, Da-Peng
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 31.12.2023; Informa UK Limited; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Animals; Biological Sciences; blood; Chromatography, Liquid; computer software; CYP3A4; drug inhibition; Drug interaction; Drug Interactions; liver microsomes; Metabolism; Metabolites; Microsomes; Microsomes, Liver - metabolism; Pharmacokinetics; Rats; Research Article; RM1-950; Statistical analysis; statistical models; tail; Tandem Mass Spectrometry; Therapeutics. Pharmacology; UPLC-MS/MS; pharmacokinetics; UPLC-MS/MS; drug inhibition; CYP3A4
• ISSN: 1388-0209; 1744-5116; 1744-5116
• DOI: 10.1080/13880209.2023.2173253

Poziotinib and vonoprazan are two drugs mainly metabolized by CYP3A4. However, the drug-drug interaction between them is unknown. To study the interaction mechanism and pharmacokinetics of poziotinib on vonoprazan. In vitro experiments were performed with rat liver microsomes (RLMs) and the contents of vonoprazan and its metabolite were then determined with UPLC-MS/MS after incubation of RLMs with vonoprazan and gradient concentrations of poziotinib. For the in vivo experiment, rats in the poziotinib treated group were given 5 mg/kg poziotinib by gavage once daily for 7 days, and the control group was only given 0.5% CMC-Na. On Day 8, tail venous blood was collected at different time points after the gavage administration of 10 mg/kg vonoprazan, and used for the quantification of vonoprazan and its metabolite. DAS and SPSS software were used for the pharmacokinetic and statistical analyses. In vitro experimental data indicated that poziotinib inhibited the metabolism of vonoprazan (IC 50  = 10.6 μM) in a mixed model of noncompetitive and uncompetitive inhibition. The inhibitory constant K i was 0.574 μM and the binding constant αK i was 2.77 μM. In vivo experiments revealed that the AUC (0- T ) (15.05 vs. 90.95 μg/mL·h) and AUC (0-∞) (15.05 vs. 91.99 μg/mL·h) of vonoprazan increased significantly with poziotinib pretreatment. The MRT (0-∞) of vonoprazan increased from 2.29 to 5.51 h, while the CLz/F value decreased from 162.67 to 25.84 L/kg·h after pretreatment with poziotinib. Poziotinib could significantly inhibit the metabolism of vonoprazan and more care may be taken when co-administered in the clinic.